PharmaSGP (PSG) Q2 2025 earnings summary

Executive summary

• Revenue increased by 13.0% year-over-year to €65,968 thousand in H1 2025, mainly driven by growth in the German market and Health Brands category.

• Adjusted EBITDA decreased by 1.4% to €16,664 thousand, with the margin dropping to 25.3% from 28.9% in H1 2024.

• Profit for the period was €8,061 thousand, down from €8,677 thousand in the prior year.

• The company completed a delisting from the Frankfurt Stock Exchange and is undergoing a squeeze-out by majority shareholder FUTRUE GmbH.

Financial highlights

• Revenue: €65,968 thousand (+13.0% year-over-year).

• Adjusted EBITDA: €16,664 thousand (-1.4% year-over-year); margin 25.3%.

• EBIT: €11,735 thousand (H1 2024: €12,162 thousand).

• Net profit: €8,061 thousand (H1 2024: €8,677 thousand).

• Basic and diluted EPS: €0.70 (H1 2024: €0.72).

• Operating cash flow: €9,884 thousand (H1 2024: €6,035 thousand).

Outlook and guidance

• Medium-term adjusted EBITDA margin expected to settle between 24.0% and 26.0% due to expansion of the pureSGP portfolio.

• Full-year 2025 forecast remains unchanged.